Single Anastomosis Sleeve Jejunal Bypass, Sleeve Gastrectomy
Conditions
Brief summary
The aim of this work is to compare the outcomes of Single Anastomosis Sleeve Jejunal Bypass (SASJ) with sleeve gastrectomy as regards efficacy including sustained weight loss, metabolic syndrome, quality of life, complications and associated comorbidities in morbid obese.
Detailed description
The most commonly performed bariatric surgery worldwide is the vertical sleeve gastrectomy (VSG), the Roux-en-Y gastric bypass (RYGB), and the One anastomosis (Mini) gastric bypass, which has been demonstrated to produce excellent bariatric and metabolic outcomes. Single anastomosis sleeve ileal (SASI) bypass was introduced in 2015 as a modification of Santorini's operation in, as it keeps pass to the duodenum so the biliary tree and the whole gut and can be assessed by the endoscope; there are no blind loops, excluded segments or foreign bodies.
Interventions
Patients underwent single anastomosis sleeve jejunal bypass as a metabolic and weight loss surgery.
PROCEDURELaparoscopic sleeve gastrectomy
Patients underwent laparoscopic sleeve gastrectomy (LGS) as a metabolic and weight loss surgery.
Sponsors
Ain Shams University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients age from 18 to 60 years old. * Both sexes. * Patients with body mass index (BMI) ≥ 40. * Patients with BMI (35 - 40) with obesity related comorbidities. (e.g. type 2 diabetes mellitus, obstructive sleep apnea, hypertension, hyperlipidemia, obesity hypoventilation syndrome, non-alcoholic fatty liver disease, gastroesophageal reflux disease and severe arthritis). * Able to be committed to follow-up.
Exclusion criteria
* Patients underwent previous Bariatric surgeries. * Patients with severe systemic disease, such as congestive heart failure - unstable angina - recent stroke or myocardial infarction less than 3 months ago. Contraindications for insufflation as those with severe cardiovascular or severe restrictive respiratory diseases. * Patients that refused to participate in the study. * Patients with psychiatric illness. * Preoperative upper GI endoscopy findings of GERD class C and Barrett's oesophagus * Previous upper GIT surgery or liver cirrhosis. * Patients on oral steroid therapy. * Not fit for general anaesthesia (e.g. patients with severe heart disease or untreatable coagulopathies). * Significant abdominal adhesions. * Major psychiatric illness. * Pregnant patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight loss | 1 month after the procedure | Weight loss was recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic syndrome | 1 month after the procedure | Metabolic syndrome was recorded. |
| Assessment of quality of life | 1 month after the procedure | quality of life was assessed using specific scoring system is a variation of the BAROS (Bariatric Analysis and Reporting Outcome System). The specific tiers you listed (High, Moderate, and Mild Improvement) * High Improvement excess Weight Loss (%EWL) \>50% + comorbidity resolution + no complications. * Moderate Improvement EWL 30-50% + partial comorbidity resolution. * Mild Improvement EWL \<30% + no major issues. |
| Incidence of complications | 1 month after the procedure | Incidence of complications such as gastroesophageal reflux disease (GERD), bile reflux, gall stones, reoperations, and postoperative bleeding were recorded. |
Countries
Egypt
Outcome results
None listed